

INTRODUCTION .....	XIII
STUDY GOALS AND OBJECTIVES .....	XIII
REASONS FOR DOING THE STUDY .....	XIII
AUDIENCE FOR THE REPORT .....	XV
SCOPE AND FORMAT .....	XVI
METHODOLOGY AND INFORMATION SOURCES.....	XVI
ABOUT THE AUTHOR.....	XVI
RELATED BCC STUDIES .....	XVII
BCC ONLINE SERVICES.....	XVII
DISCLAIMER .....	XVII
EXECUTIVE SUMMARY .....	XVIII
<i>SUMMARY TABLE REVENUES FOR SELECTED DRUG DISCOVERY-RELATED PRODUCTS, WORLDWIDE FORECAST, THROUGH 2012 (\$ MILLIONS)</i> .....	XVIII
<i>SUMMARY FIGURE REVENUES FOR SELECTED DRUG DISCOVERY-RELATED PRODUCTS, WORLDWIDE FORECAST, 2006-2012 (\$ MILLIONS)</i> .....	XIX
DRUG DISCOVERY TECHNOLOGIES AND R&D EFFORTS .....	XIX
OVERALL DRUG DISCOVERY MARKET TO 2012 .....	XX
OVERVIEW .....	1
GOVERNMENT REGULATIONS .....	2
INTRODUCTION.....	2
DRUG DISCOVERY.....	3
PRECLINICAL TESTING AND SUBMISSION OF AN IND .....	4
CLINICAL TRIALS.....	5
TIMELINE AND COSTS .....	6
SUBMISSION OF NDA OR BLA .....	7
POST-FDA APPROVAL.....	8
NEW DRUG APPROVALS .....	8
<i>FIGURE 1 FDA APPROVALS OF NEW MOLECULAR ENTITIES SINCE 1993</i> .....	9
<i>TABLE 1 NEW MOLECULAR ENTITIES APPROVED BY THE FDA, 1990–OCTOBER 2007</i> .....	10
DO CURRENT CORPORATE MANAGEMENT PRACTICES HAVE A ROLE IN R&D SHORTFALLS?.....	11
Blockbuster Drugs .....	12
<i>TABLE 2 NME APPROVALS BY DISORDER, 2004–OCTOBER 30, 2007</i> .....	13
Other Successful Therapeutic Agents.....	14
<i>TABLE 3 BOTOX SALES, 1993–2012 (\$ MILLIONS)</i> .....	14

IS THE NIH FUNDING CRISIS CONTRIBUTING TO SHORTFALLS IN DRUG DISCOVERY? .....	15
IS THE NIH FUNDING CRISIS CONTRIBUTING...(CONTINUED) .....	16
TRENDS IN BIG PHARMA DRUG DISCOVERY AND INVESTMENTS IN DRUG DISCOVERY.....	17
BIG PHARMA .....	17
<i>TABLE 4 THE WORLD PHARMACEUTICALS MARKET, THROUGH     2012 (\$ BILLIONS)</i> .....	17
<i>FIGURE 2 THE WORLD PHARMACEUTICALS MARKET, 2005-2012     (\$ BILLIONS)</i> .....	17
BIG PHARMA (CONTINUED).....	18
<i>TABLE 5 COMPARATIVE PERCENTAGES OF REVENUES AT THE     SIX LARGEST U.S. PHARMACEUTICAL COMPANIES</i> .....	19
<i>TABLE 6 COMPARISON OF FDA APPROVED NME DRUGS     DEVELOPED IN HOUSE OR THROUGH IN-LICENSING, 2006 AND     H1 2007</i> .....	19
VENTURE CAPITAL.....	20
VENTURE CAPITAL (CONTINUED) .....	21
LIQUID CHROMATOGRAPHY (LC) .....	22
<i>TABLE 7 WORLD MARKETS FOR HPLC, THROUGH 2012     (\$ MILLIONS)</i> .....	22
<i>FIGURE 3 WORLD MARKETS FOR HPLC, 2006-2012 (\$ MILLIONS)</i> .....	22
HPLC AND UHPLC: THEORY .....	23
HPLC AND UHPLC: THEORY (CONTINUED) .....	24
ULTRA-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (UHPLC, UPLC).....	25
HPLC & UPLC INSTRUMENTS .....	26
Sample Injection Systems .....	26
Pumps .....	27
Columns .....	27
DRIVERS OF GROWTH IN LIQUID CHROMATOGRAPHY SYSTEMS.....	28
Proteomics Research.....	28
FDA and Other Regulatory Body Requirements.....	28
Drug Discovery Research in Small and Medium Sized Companies .....	28
The Growth of the Research Enterprise Overseas.....	28
New Instrument Designs .....	29
CHALLENGES TO GROWTH IN LIQUID CHROMATOGRAPHY SYSTEMS .....	29
Technology Maturity .....	29
Throughput Speed .....	30

Stagnation and/or Reduction of the NIH Budget .....	31
MARKET LEADERS .....	32
<i>TABLE 8 MARKET LEADERS IN HPLC, 2006 (%)</i> .....	32
MASS SPECTROMETRY (MS) .....	33
<i>TABLE 9 MARKETS FOR MASS SPECTROMETRY, THROUGH 2012</i> (\$ MILLIONS) .....	33
<i>FIGURE 4 MARKETS FOR MASS SPECTROMETRY, 2006-2012</i> (\$ MILLIONS) .....	33
MASS SPECTROMETRY (CONTINUED) .....	34
<i>TABLE 10 MARKET LEADERS IN MASS SPECTROMETRY, 2006 (%)</i> .....	35
MASS SPECTROMETRY: THEORY AND INSTRUMENT TYPES .....	36
IONIZATION SOURCES .....	37
Matrix-assisted Laser Desorption/Ionization (MALDI) .....	37
Electrospray Ionization (ESI) .....	37
Atmospheric Pressure Chemical Ionization (APCI) .....	37
MASS ANALYZERS .....	38
<i>TABLE 11 TYPES OF MASS SPECTROMETRY ANALYZERS USED IN</i> <i>PHARMACEUTICAL APPLICATIONS</i> .....	38
Quadrupole .....	38
Time-of-Flight Mass Spectrometry .....	39
Quadrupole—Time-of-Flight (Q-TOF) .....	40
<i>TABLE 12 SELECTED Q-TOF MODELS</i> .....	40
ION TRAP MASS SPECTROSCOPY .....	41
<i>TABLE 13 SELECTED ION TRAP MASS SPECTROMETER MODELS</i> .....	41
DRIVERS OF GROWTH AND CHALLENGES IN MASS SPECTROMETRY .....	42
Drivers of Growth and Challenges...(Continued) .....	43
COMPANY PROFILES: LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY .....	44
COMPANY PROFILES .....	44
DETAILED PROFILES .....	44
Agilent Technologies .....	44
Applera Corp. ....	45
Applied Biosystems .....	45
Beckman Coulter .....	45
Bruker Daltonics .....	46
Dionex .....	46
Eksigent .....	47
ESA Biosciences .....	47
Jasco, Inc. ....	48
JEOL USA .....	48
MDS Sciex .....	48
PerkinElmer Corporation .....	49

Phenomenex Corporation .....	49
Shimadzu .....	50
Thermo Fisher Scientific .....	50
Varian, Inc. ....	51
Waters Corp. ....	51
<b>BRIEF PROFILES .....</b>	<b>52</b>
Aapttec LLC .....	52
Advanced Chemistry Development, Inc. (ACD/Labs) .....	52
Advanced Chromatography Technologies (ACE) .....	53
Advanced Scientific Instruments: See Knauer.....	53
Advanced Separation Technologies (Astec) .....	53
Advion .....	53
Alpha Omega Technologies .....	54
Ametek Process and Analytical Instruments (Ametek PI) .....	54
Ampersand International, Inc.....	54
Analytical Scientific Instruments, Inc. (ASI) .....	55
Applied Research Europe GmbH .....	55
Ardara Technologies, LP .....	55
B/R Instrument Corporation .....	56
Bischoff Chromatography.....	56
BioTrove .....	56
BSG, Inc. ....	57
Burle Electro-Optics/ Photonis Group .....	57
Cecil Instruments Ltd. ....	57
Cerno Bioscience.....	58
Chrom Tech, Inc.....	58
Dychrom .....	59
ES Industries .....	59
Gilson .....	59
International Equipment Trading (IET) Ltd.....	60
IonSense, Inc.....	60
Ion Square Technology, Inc. ....	60
Isolation Technologies, Inc. ....	61
Justrite Manufacturing Co.....	61
Knauer/Advanced Scientific Instruments .....	61
Konik Instruments .....	61
Kromasil/Akzo Nobel .....	62
Lab Alliance/Scientific Systems Inc. (SSI) .....	62
Macherey-Nagel, GmbH & Co. KG .....	62
Moeller Medical GmbH .....	63
Molnar Institute .....	64
NCSRT Inc. ....	64
Nova Biotech.....	64
Ocean Optics Inc.....	64

Optimize Technologies Inc. ....	65
Phytronix Technologies, Inc. ....	65
Quantum Analytics.....	65
Sonnatek .....	66
Spark Holland BV.....	66
SRI Instruments .....	66
VICI Valco Instruments Company Inc. ....	67
YMC Ltd.....	67
Zinsser Analytic GmbH .....	68
<b>HIGH CONTENT SCREENING (HCS).....</b>	<b>69</b>
<i>TABLE 14 MARKETS FOR HCS, THROUGH 2012 (\$ MILLIONS)</i> .....	69
<i>FIGURE 5 MARKETS FOR HCS, 2006-2012 (\$ MILLIONS)</i> .....	69
HCS: THEORY.....	70
<i>TABLE 15 HCS INSTRUMENT LINES</i> .....	71
<i>TABLE 16 MARKET LEADERS IN HCS INSTRUMENTS, 2006</i> .....	71
DRIVERS OF GROWTH IN HCS.....	72
Information Output .....	72
The Growth of Contract Research Organizations (CROs) .....	72
The Growth of the Research Enterprise Overseas.....	72
Requirements for Pathway Knowledge .....	72
CHALLENGES TO GROWTH IN HCS .....	73
Costs .....	73
Drug Discovery Research in Small- and Medium Sized Companies .....	73
Stagnation and/or Reduction of the NIH Budget .....	74
Complexity .....	74
COMPANY PROFILES .....	74
CELLOMICS/THERMO FISHER .....	74
GE HEALTHCARE .....	75
COMPUCYTE CORPORATION.....	75
TTP LABTECH .....	75
EVOTEC TECHNOLOGIES/PERKINELMER.....	76
IMSTAR SA .....	76
<b>BIOINFORMATICS.....</b>	<b>77</b>
<i>TABLE 17 THE U.S. MARKET FOR BIOINFORMATICS SOFTWARE     APPLICATIONS AND DATABASES/KNOWLEDGE BASES,     THROUGH 2012 (\$ MILLIONS)</i> .....	77
<i>FIGURE 6 THE U.S. MARKET FOR BIOINFORMATICS SOFTWARE     APPLICATIONS AND DATABASES/KNOWLEDGE BASES, 2006-     2012 (\$ MILLIONS)</i> .....	77
WHAT IS BIOINFORMATICS? .....	78
The First Wave of Bioinformatics Companies: Lessons Learned.....	78

<i>TABLE 18 ANNUAL BIOINFORMATICS-RELATED REVENUES AT SELECTED COMPANIES, 2000-2007 (\$ MILLIONS, ROUNDED)</i> .....	79
<i>TABLE 19 FREE MAJOR ONLINE SOURCES OF GENOMIC AND PROTEOMIC INFORMATION</i> .....	80
<i>TABLE 20 SOME COMMERCIAL SOURCES OF GENOMIC AND PROTEOMIC INFORMATION</i> .....	80
<i>TABLE 20 (CONTINUED)</i> .....	81
Source: BCC Research .....	81
The Second Wave of Bioinformatics Companies: Lessons Applied in a Difficult Market.....	81
<i>TABLE 21 BIOINFORMATICS: MARKET LEADERS AND STRUGGLING COMPANIES</i> .....	81
The Second Wave of...(Continued) .....	82
MICROARRAYS: COMBINING BIOINFORMATICS AND BENCH RESEARCH .....	83
<i>TABLE 22 MARKETS FOR COMMERCIAL MICROARRAYS (\$ MILLIONS)</i> .....	83
Microarrays: Combining...(Continued).....	84
OPEN SOURCE TOOLS AND IN-HOUSE BIOINFORMATICS .....	85
Bioinformatics Software Not Related to Drug Discovery .....	86
EMPLOYMENT OUTLOOK IN BIOINFORMATICS.....	86
Employment Outlook in ... (Continued) .....	87
TYPICAL DEVELOPMENT PATTERNS IN BIOINFORMATICS .....	88
GAPS IN BIOINFORMATICS .....	89
GAPS IN BIOINFORMATICS (CONTINUED) .....	89
FUTURE TRENDS IN BIOINFORMATICS .....	90
COMPANY PROFILES .....	91
ACCELRY'S, INC. (NASDAQ: ACCL) .....	91
AFFYMETRIX, INC. ....	92
GENE LOGIC, INC. ....	93
GEOSPIZA.....	93
INCYTE .....	94
PROTEOME SYSTEMS.....	94
SPOTFIRE .....	95
VIZX LABS, INC. ....	96
VLST CORPORATION .....	96
VLST Corporation (Continued).....	97
SYSTEMS BIOLOGY .....	98
SYSTEMS BIOLOGY.....	98
<i>TABLE 23 THE MARKET FOR SYSTEMS BIOLOGY (\$ MILLIONS)</i> .....	99
CATEGORIES OF SYSTEMS BIOLOGY COMPANIES .....	99
Pathway providers.....	99
Model Makers .....	100

USES OF SYSTEMS BIOLOGY.....	100
Uses of Systems Biology (Continued) .....	101
<i>TABLE 24 SYSTEMS BIOLOGY COMPANIES (\$ MILLIONS)</i> .....	<i>102</i>
CHALLENGES IN SYSTEMS BIOLOGY .....	103
COMPANY PROFILES .....	104
ARIADNE GENOMICS.....	104
BG MEDICINE.....	104
BIOSEEK.....	105
ENTELOS (LONDON AIM: ENTL) .....	105
GENEGO .....	106
GENE NETWORK SCIENCES (GNS).....	107
GENOMATICA.....	107
GENSTRUCT .....	108
INGENUITY SYSTEMS .....	109
U.S. PATENT ANALYSIS.....	110
INTRODUCTION .....	110
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC).....	110
GENERAL TRENDS.....	111
<i>TABLE 25 HPLC-RELATED TECHNOLOGY: U.S. PATENT TRENDS,</i> <i>5/2002–8/2007 .....</i>	<i>111</i>
<i>TABLE 26 MS-RELATED PATENTS BY USE CATEGORY .....</i>	<i>112</i>
TRENDS BY ASSIGNEE .....	113
<i>TABLE 27 HPLC-RELATED PATENTS BY ASSIGNEE CATEGORY.....</i>	<i>113</i>
<i>TABLE 28 HPLC-RELATED PATENTS BY COMPANY .....</i>	<i>114</i>
PATENT APPLICATION TRENDS.....	115
<i>TABLE 29 HPLC-RELATED TECHNOLOGY, U.S. PATENT</i> <i>APPLICATION TRENDS, 2001-8/2/2007.....</i>	<i>116</i>
<i>TABLE 30 HPLC-RELATED TECHNOLOGY: U.S. PATENT</i> <i>APPLICATION TRENDS BY FILING DATE, 1997–8/2007 .....</i>	<i>117</i>
<i>TABLE 31 MS-RELATED PATENTS BY USE CATEGORY .....</i>	<i>117</i>
MASS SPECTROMETRY (MS).....	118
<i>TABLE 32 MS-RELATED TECHNOLOGY: U.S. PATENT TRENDS,</i> <i>1976–8/7/2007 .....</i>	<i>118</i>
GENERAL TRENDS.....	119
<i>TABLE 33 MS-RELATED PATENTS BY USE CATEGORY .....</i>	<i>120</i>
TRENDS BY ASSIGNEE .....	120
<i>TABLE 34 MS-RELATED PATENTS BY ASSIGNEE CATEGORY .....</i>	<i>121</i>
<i>TABLE 35 MS-RELATED PATENTS BY COMPANY.....</i>	<i>121</i>
PATENT APPLICATION TRENDS.....	122
<i>TABLE 36 MS-RELATED TECHNOLOGY, U.S. PATENT</i> <i>APPLICATION TRENDS, 2001–8/2/2007.....</i>	<i>122</i>
<i>TABLE 37 MS-RELATED TECHNOLOGY, U.S. PATENT</i> <i>APPLICATION TRENDS BY FILING DATE, 1997–8/2007 .....</i>	<i>123</i>
<i>TABLE 38 MS-RELATED PATENTS BY USE CATEGORY .....</i>	<i>123</i>

PATENT APPLICATION TRENDS (CONTINUED) .....	124
APPENDIX A SELECTION OF OPEN-ACCESS AND FEE-BASED SOURCES FOR GENOMIC AND PROTEOMIC DATA .....	125
GENOMICS-RELATED DATABASES .....	125
PROTEOMICS DATABASES.....	126
PROTEIN INTERACTION DATABASES (INTERACTOME DATABASES).....	126
Other Proteomics Databases.....	127
SYSTEMS BIOLOGY.....	128
OTHER DATABASES USEFUL FOR DRUG DISCOVERY: .....	128